The US Food and Drug Administration (FDA) is requiring that a number of safety measures be adopted, including changes to ponatinib’s label to narrow t...
The Centers for Disease Control and Prevention (CDC) has identified a
small group of newborns in Tennessee with late vitamin K deficiency
bleeding (...
The US Food and Drug Administration (FDA) has has granted accelerated approval for
ibrutinib (Imbruvica) to treat patients with mantle cell lymphoma ...
The agency placed current ponatinib trials on partial clinical hold and asked the drug’s makers, Ariad Pharmaceuticals, to end the phase 3 EPIC trial....
All trials of ponatinib were placed on partial clinical hold on October 9, after follow-up data from the phase 2 PACE trial revealed an increased inci...
